Article Text

Download PDFPDF

FRI0299 N-terminal pro-brain natriuretic peptide (NT-PROBNP) level in patients with untreated systemic lupus erythematosus
Free
  1. T Panafidina,
  2. M Sokhova,
  3. T Popkova,
  4. D Novikova,
  5. E Alexandrova,
  6. E Nasonov
  1. V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Abstract

Objectives The aim of this study was to determine NT-proBNP serum levels in patients with untreated SLE, thus ruling out any potential effect of SLE therapy: to analyze any possible correlation between NT-proBNP values and traditional risk factors (TRF), inflammatory markers and myocardial function parameters.

Methods The study included 28 pts (82% females, aged 28,5 [25,0–32,0] years (median [interquartile range 25%>75%]) with untreated SLE (ACR criteria, 1997) and 27 healthy controls (89% females, age 30,0 [23,0–49,0] years). None of SLE pts was treated either with prednisone or cytotoxic drugs at the moment of inclusion, 5 (18%) pts received hydroxychloroquine 200 mg/day. SLE-related factors, including disease duration, clinical features, SLE Disease Activity Index (SLEDAI 2K) and Systemic Lupus International Collaborating Clinics damage index (SLICC/DI) were evaluated in parallel with relevant laboratory findings (blood and urine tests, CRP, IL-6, INF-α, immunoglobulins G, A and M, C3 and C4 complement fragments and others), autoantibodies (ANA, antiDNA, ENA-SSA, -SSB, -Sm, -RNP-70, aPL), echocardiography was performed using standard techniques. Serum levels of NT-proBNP (pg/ml) were measured using electrochemiluminescence method Elecsys proBNP II (Roche Diagnostics, Switzerland). Normal NT-proBNP levels should vary within ≤125,0 pg/mL.

Results Mean SLE duration was 21,0 [5,0–60,0] months, SLEDAI 2K score - 11 [8–9], SLICC/DI score - 0 [0–0]. SLE pts had higher levels of NT-proBNP vs control (160,7 [88,6–335,4] vs 55,2 [36,6–70,3] pg/ml, p<0,001). Elevated levels of NT-proBNP (>125,0 pg/ml) was detected in 18 (64%) SLE pts. In SLE pts NT-proBNP serum levels showed positive correlation with creatinine (r=0,480, p<0,01), uric acid (r=0,427, p<0,05), ACL IgG (r=0,710, p<0,001), antiDNA (r=0,395, p<0,05), ANA levels (r=0,256, p<0,05), left ventricle (LV) end-systolic dimension (r=0,442, p<0,05), mean pulmonary artery pressure (r=0,486, p<0,05); and negative correlation with hemoglobin level (r=-0,493, p<0,01), C4 complement component (r=-0,475, p<0,05), glomerular filtration rate (r=-0,558, p<0,01) and LV ejection fraction (r=-0,505, p<0,01); left ventricular diastolic dysfunction (DDLV) was only in pts with NT-proBNP levels >125,0 pg/ml. Mean NT-proBNP concentration in verified DDLV cases (n=5 (18%)) considerably exceeded normal values, reaching up to 799,2 [276,6–1777,0] pg/ml.

Conclusions Untreated SLE patients without a history of myocardial infarction, coronary procedure or any evidence of heart failure demonstrated higher NT-proBNP concentration as compared to healthy controls (p<0,001). NT-proBNP levels showed correlation with numerous SLE markers (ACL IgG, ANA, antiDNA, C4 fragment of complement), kidney function (creatinine, uric acid, glomerular filtration rate) and myocardial function (end-systolic dimension of the LV, mean pulmonary artery pressure, LV ejection fraction). No correlation was documented between NT-proBNP concentration and TRF or inflammatory markers (CRP, IL-6, INF-α). All abovementioned data suggest presumable SLE-associated autoimmune damage of cardiomyocytes and/or mediated decrease of myocardial function caused by kidney disease.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.